Passage BIO (PASG) Return on Capital Employed (2020 - 2026)
Passage BIO (PASG) posted quarterly Return on Capital Employed of 140.37% for Q1 2026, down 5029.0% year-over-year from 2.85% in Q1 2025, and down 28.53% quarter-over-quarter from 109.21% in Q4 2025.
Passage BIO (PASG) Return on Capital Employed (2020 - 2026) Analysis & Trends
Passage BIO's Return on Capital Employed history runs 7 years deep, the most recent figure standing at 140.37% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 5029.0% year-over-year to 140.37%; the TTM figure through Mar 2026 stood at 140.37% (down 5029.0% YoY), while the FY2025 annual figure was 83.18%, down 1746.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 140.37%, down from 109.21% in the prior quarter.
- The five-year high for Return on Capital Employed was 58.04% in Q4 2022, with the low at 140.37% in Q1 2026.
- The 5-year median for Return on Capital Employed is 73.11% (2023), against an average of 78.59%.
- The sharpest annual moves came in 2024 and 2026: Return on Capital Employed declined 28 bps in 2024, then slumped 5029 bps in 2026.
- Passage BIO's Return on Capital Employed stood at 58.04% in 2022, then plunged by 30 bps to 75.5% in 2023, then slipped by 6 bps to 80.26% in 2024, then slumped by 36 bps to 109.21% in 2025, then fell by 29 bps to 140.37% in 2026.
- Business Quant data shows PASG's Return on Capital Employed at 140.37% in Q1 2026, 109.21% in Q4 2025, and 91.34% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Passage BIO | 15.05 Mn | 15.05 Mn | - | -386.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -386.38% |
| Mar 31, 2026 | -140.37% |
| Dec 31, 2025 | -109.21% |
| Sep 30, 2025 | -91.34% |
| Jun 30, 2025 | -98.35% |
| Mar 31, 2025 | -90.08% |
| Dec 31, 2024 | -80.26% |
| Sep 30, 2024 | -73.39% |
| Jun 30, 2024 | -68.46% |
| Mar 31, 2024 | -68.24% |
| Dec 31, 2023 | -75.50% |
| Sep 30, 2023 | -73.11% |
| Jun 30, 2023 | -63.75% |
| Mar 31, 2023 | -62.26% |
| Dec 31, 2022 | -58.04% |
| Sep 30, 2022 | -61.31% |
| Jun 30, 2022 | -62.55% |
| Mar 31, 2022 | -59.88% |
| Dec 31, 2021 | -54.07% |
| Sep 30, 2021 | -44.18% |